BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35227076)

  • 21. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
    Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
    Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of prolactin receptor expression in breast cancer subtypes].
    Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF
    Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.
    Loibl S; Müller BM; von Minckwitz G; Schwabe M; Roller M; Darb-Esfahani S; Ataseven B; du Bois A; Fissler-Eckhoff A; Gerber B; Kulmer U; Alles JU; Mehta K; Denkert C
    Breast Cancer Res Treat; 2011 Nov; 130(2):477-87. PubMed ID: 21837479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lin28A and androgen receptor expression in ER-/Her2+ breast cancer.
    Shen H; Yang Y; Zhao L; Yuan J; Niu Y
    Breast Cancer Res Treat; 2016 Feb; 156(1):135-47. PubMed ID: 26944953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
    Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
    Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
    BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.
    Park S; Lee SK; Paik HJ; Ryu JM; Kim I; Bae SY; Yu J; Kim SW; Lee JE; Nam SJ
    Medicine (Baltimore); 2017 Jun; 96(22):e6777. PubMed ID: 28562530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
    Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
    Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer.
    Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y
    Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
    Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.
    Singh LC; Chakraborty A; Mishra AK; Devi TR; Sugandhi N; Chintamani C; Bhatnagar D; Kapur S; Saxena S
    Med Oncol; 2012 Jun; 29(2):539-46. PubMed ID: 21528410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
    Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
    Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
    Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
    Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
    Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
    [No Abstract]   [Full Text] [Related]  

  • 38. [Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status].
    Chen J; Zhang X; Tian R; Liu Y; Dong HM; Guo RF; Liang HY
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):743-6. PubMed ID: 21215164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic and prognostic role of NR3C4 in breast cancer through a genomic network understanding.
    Song Y; Huang R; Wu S; Zheng H; Guo M; Fu L; Yu S
    Pathol Res Pract; 2021 Jan; 217():153310. PubMed ID: 33348168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.